COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,635 Articles (22,913 medRxiv, 8,722 bioRxiv)

Most recent first Previous |  Page 959: Articles 9581-9590  | Next

A novel SEIR-e model for disease transmission and pathogen exposure
Tambyah, T. A., Testolin, M. J., Hill, A. M.
10.1101/2022.02.16.22271093 — Posted: 2022-02-17
Analytical Sensitivity of the SalivaDirect™ Assay on the Liberty16 for detecting SARS-CoV-2 B.1.1.529 Omicron
Tan, Y. P., Al-Halbouni, M., Chen, C.-H., Hirst, D. B., Pickering, P. J.
10.1101/2022.02.16.22271096 — Posted: 2022-02-17
Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces robust neutralizing salivary IgA
Stolovich-Rain, M., Kumari, S., Friedman, A., Kirillov, S., Socol, Y., Billan, M., Ranjan Pal, R., Golding, P., Oiknine-Djian, E., Sirhan, S., Bejerano Sagie, M., Cohen-Kfir, E., Elgrably-Weiss, M., Zhou, B., Ravins, M., E Gatt, Y., Das, K., Zelig, O., Wiener, R., Wolf, D., Elinav, H., Strahilevitz, J., Padawer, D., Baraz, L., Rouvinski, A.
10.1101/2022.02.17.480851 — Posted: 2022-02-17
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
Du, W., Hurdiss, D. L., Drabek, D., Mykytyn, A. Z., Kaiser, F., Gonzalez-Hernandez, M., Munoz-Santos, D., Lamers, M. M., van Haperen, R., Li, W., Drulyte, I., Wang, C., Sola, I., Armando, F., Beythien, G., Ciurkiewicz, M., Baumgartner, W., Guilfoyle, K., Smits, T., van der Lee, J., van Kuppeveld, F. J. M., van Amerongen, G., Haagmans, B. L., Enjuanes, L., Osterhaus, A. D., Grosveld, F., Bosch, B. J.
10.1101/2022.02.17.480751 — Posted: 2022-02-17
A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models.
Narayan, R., Sharma, M., Yadav, R. T., Biji, A., Khatun, O., Rajmani, R. S., Sharma, P. R., Jeyashankar, S., Rani, P., Rao, C. D., Satchidanandam, V., Das, S., Agarwal, R., Tripathi, S.
10.1101/2022.02.16.480801 — Posted: 2022-02-17
Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts
Mascaro, S., Wu, Y., Woodberry, O., Nyberg, E. P., Pearson, R., Ramsay, J. A., Mace, A., Foley, D., Snelling, T., Nicholson, A. E.
10.1101/2022.02.14.22270925 — Posted: 2022-02-17
Effectiveness and safety of PRP on persistent olfactory dysfunction related to COVID-19: towards a new therapeutic hope
steffens, y., Lebon, S.-D., Prunier, L., Rodiguez, A. r., Lechien, J., Saussez, S., Horoi, M.
10.1101/2022.02.14.22270109 — Posted: 2022-02-17
Bioinformatic analysis of B and T cell epitopes from SARS-CoV-2 Spike, Membrane and Nucleocapsid proteins as a strategy to assess possible cross-reactivity between emerging variants, including Omicron, and other human coronaviruses
Pacheco, D. L., Saint Remy, S., Garcia, M. G., Rivera, T., Lopez, C. R.
10.1101/2022.02.16.480759 — Posted: 2022-02-17
Biomechanical dependence of SARS-CoV-2 infections
Paul, A., Kumar, S., Kaoud, T., Pickett, M. R., Bohanon, A. L., Zoldan, J., Dalby, K. N., Parekh, S. H.
10.1101/2022.02.17.479764 — Posted: 2022-02-17
Validation of the RT-LAMP assay in a large cohort of nasopharyngeal swab samples shows that it is a useful screening method for detecting SARS-CoV-2 and its VOC variants
Cisneros-Villanueva, M., Blancas, S. S., Cedro-Tanda, A., Rios-Romero, M., Hurtado-Cordova, E., Almaraz-Rojas, O., Ortiz-Soriano, D. R., Alvarez-Hernandez, V., Arriaga-Guzman, I. E., Tolentino-Garcia, L., Sanchez-Vizcarra, A., Lozada-Rodriguez, L. F., Peralta-Arrieta, I., Perez-Aquino, J. E., Andonegui-Elguera, M. A., Cendejas-Orozco, M., Mendoza-Vargas, A., Reyes-Grajeda, J. P., Campos-Romero, A., Alcantar-Fernandez, J., Moreno-Camacho, J. L., Gallegos-Rodriguez, J., Esparza-Luna-Ruiz, M., Ortiz-Ramirez, J., Benitez-Gonzalez, M., Uribe-Figueroa, L., Angulo, O., Ruiz, R., Herrera, L. A., Hidalgo-Miranda, A.
10.1101/2022.02.15.22270954 — Posted: 2022-02-17

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).